Accordingly, CD103 blockade alleviates intestinal immunopathology in both SMAD4-deficient mice and human patients with Crohn’s disease (43), pinpointing the central role of gut epithelial retention of CD8+ T cells in IBD development. Here, SMAD4 is linked to inflammatory bowel disease.